Literature DB >> 17058280

Viral and atypical bacterial infections in the outpatient pediatric cystic fibrosis clinic.

Hanne Vebert Olesen1, Lars P Nielsen, Peter Oluf Schiotz.   

Abstract

BACKGROUND: Respiratory viral and atypical bacterial infections are associated with pulmonary exacerbations and hospitalisations in cystic fibrosis patients. We wanted to study the impact of such infections on children attending the outpatient clinic.
METHODS: Seventy-five children were followed for 12 months at regular clinic visits. Routine sputum/laryngeal aspirations were tested with PCR for 7 respiratory viruses. Antibodies against C. pneumoniae, M. pneumoniae and B. pertussis were measured every 3-4 months. FEV-1, FEF(25-75) and specific airway resistance, "viral" symptoms and bacterial culture were recorded.
RESULTS: Ninety-seven viral and 21 atypical bacterial infections were found. FEV-1 was significantly reduced during viral infection (-12.5%, p=0.048), with the exception of rhinovirus infection. A small change in FEV-1 (-3%) was seen during atypical bacterial infection (p=0.039). Viral and atypical bacterial infections caused no change in type and frequency of bacterial culture. Positive predictive value of "viral symptoms" was low (0.64%). Eight patients received "unnecessary" antibiotics because of viral symptoms.
CONCLUSIONS: Some viral infections and atypical bacterial infections affect FEV-1 acutely. Viral infections did not precipitate bacterial infection or change of colonisation. Clinical symptoms failed to diagnose viral infection accurately. Routine surveillance for virus or atypical bacteria seems not to be justified in this patient category.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17058280     DOI: 10.1002/ppul.20517

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  24 in total

1.  Pulmonary exacerbations in cystic fibrosis with negative bacterial cultures.

Authors:  Edith T Zemanick; Brandie D Wagner; J Kirk Harris; Jeffery S Wagener; Frank J Accurso; Scott D Sagel
Journal:  Pediatr Pulmonol       Date:  2010-06

Review 2.  Spectrum of viral infections in patients with cystic fibrosis.

Authors:  H Frickmann; S Jungblut; T O Hirche; U Groß; M Kuhns; A E Zautner
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2012-09-10

Review 3.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

4.  Influenza vaccination in children at high risk of respiratory disease.

Authors:  Maria Francesca Patria; Claudia Tagliabue; Benedetta Longhi; Susanna Esposito
Journal:  Ther Adv Vaccines       Date:  2013-05

Review 5.  Cystic fibrosis: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases.

Authors:  Jessica E Pittman; Garry Cutting; Stephanie D Davis; Thomas Ferkol; Richard Boucher
Journal:  Ann Am Thorac Soc       Date:  2014-04

6.  Differential responses to rhinovirus- and influenza-associated pulmonary exacerbations in patients with cystic fibrosis.

Authors:  Ixsy A Ramirez; Lindsay J Caverly; Lindsay L Caverly; Linda M Kalikin; Adam M Goldsmith; Toby C Lewis; David T Burke; John J LiPuma; Uma S Sajjan; Marc B Hershenson
Journal:  Ann Am Thorac Soc       Date:  2014-05

Review 7.  Duration of intravenous antibiotic therapy in people with cystic fibrosis.

Authors:  Amanda Plummer; Martin Wildman; Tim Gleeson
Journal:  Cochrane Database Syst Rev       Date:  2016-09-01

Review 8.  The changing microbial epidemiology in cystic fibrosis.

Authors:  John J Lipuma
Journal:  Clin Microbiol Rev       Date:  2010-04       Impact factor: 26.132

Review 9.  Human rhinoviruses.

Authors:  Samantha E Jacobs; Daryl M Lamson; Kirsten St George; Thomas J Walsh
Journal:  Clin Microbiol Rev       Date:  2013-01       Impact factor: 26.132

10.  Rhinovirus C and respiratory exacerbations in children with cystic fibrosis.

Authors:  Marina B de Almeida; Rodrigo M Zerbinati; Adriana F Tateno; Cristina M Oliveira; Renata M Romão; Joaquim C Rodrigues; Cláudio S Pannuti; Luiz Vicente F da Silva Filho
Journal:  Emerg Infect Dis       Date:  2010-06       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.